Hutchison China MediTech Limited Sponsored ADR Aktie News

HUTCHMED (China) Limited ( HCM ) HUTCHMED (China) Limited Deutsche Bank ADR Virtual Investor Conference 2025 November 4, 2025 8:00 AM EST Company Participants David Ng - Head of Investor Relations & Capital Strategies Conference Call Participants Zafar Aziz - Deutsche Bank Aktiengesellschaft Presentation Zafar Aziz Deutsche Bank Aktiengesellschaft Hello, and Welcome to Deutsche Bank's Virtual I...

— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —

HUTCHMED (China) Limited ( HCM ) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update October 31, 2025 8:00 AM EDT Company Participants David Ng - Head of Investor Relations & Capital Strategies Ming Shi - Executive VP, Head of R&D and Chief Medical Officer Conference Call Participants Alec Stranahan - BofA Securities, Research Division Khalil Fenin...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025.

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2025, taking place on October 17-21, 2025 in Berlin, Germany.

— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 — — HUTCHMED will host in-person presentation and online webinar on Friday, October 31 —

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2025 World Conference on Lung Cancer (“WCLC”) taking place on September 6-9, 2025 in Barcelona, Spain, and the Chinese Societ...